Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion
- 15 September 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 180 (6) , 558-563
Abstract
Rationale: Cavitary disease and delayed culture conversion have been associated with relapse. Combining patient characteristics and measures of bacteriologic response might allow treatment shortening with current drugs in some patients. Objectives: To assess whether treatment could be shortened from 6 to 4 months in patients with noncavitary tuberculosis whose sputum cultures converted to negative after 2 months. Methods: This study was a randomized, open-label equivalence trial. HIV-uninfected adults with noncavitary tuberculosis were treated daily with isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months, followed by 2 months of isoniazid and rifampin. After 4 months, patients with drug-susceptible TB whose sputum cultures on solid media were negative after 8 weeks of treatment were randomly assigned to continue treatment for 2 more months or to stop treatment. Patients were followed for relapse for 30 months after beginning treatment. Measurements and Main Results: Enrollment was stopped by the safety monitoring committee after 394 patients were enrolled due to apparent increased risk for relapse in the 4-month arm. A total of 370 patients were eligible for per protocol analysis. Thirteen patients in the 4-month arm relapsed, compared with three subjects in the 6-month arm (7.0 vs. 1.6%; risk difference, 0.054; 95% confidence interval with Hauck-Anderson correction, 0.01–0.10). Conclusion: Shortening treatment from 6 to 4 months in adults with noncavitary disease and culture conversion after 2 months using current drugs resulted in a greater relapse rate. The combination of noncavitary disease and 2-month culture conversion was insufficient to identify patients with decreased risk for relapse.Keywords
Funding Information
- Case Western Reserve University (NO1-AI95383)
- Case Western Reserve University (HHSN266200700022C/NO1-AI-70022)
This publication has 32 references indexed in Scilit:
- Biomarkers for tuberculosis disease activity, cure, and relapseThe Lancet Infectious Diseases, 2009
- Cavitary Disease and Quantitative Sputum Bacillary Load in Cases of Pulmonary TuberculosisJournal of Clinical Microbiology, 2007
- Diarylquinolines target subunit c of mycobacterial ATP synthaseNature Chemical Biology, 2007
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLOS Medicine, 2006
- A controlled trial of six months chemotherapy in pulmonary tuberculosis: First report: Results during chemotherapyRespiratory Medicine, 2004
- Pulmonary tuberculosis: relationship between sputum bacilloscopy and radiological lesionsRevista do Instituto de Medicina Tropical de São Paulo, 2003
- Understanding the chemotherapy of tuberculosis—current problemsJournal of Antimicrobial Chemotherapy, 1992
- Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South IndiaTubercle, 1990
- A Comparison of Large-Sample Confidence Interval Methods for the Difference of Two Binomial ProbabilitiesThe American Statistician, 1986
- The action of antituberculosis drugs in short-course chemotherapyTubercle, 1985